The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Erichev V.P.

FGBU "Nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ" RAMN, Moskva

Petrov S.Iu.

FGBU "NII glaznykh bolezneĭ" RAMN

Volzhanin A.V.

Research Institute of Eye Diseases, 11, A, B, Rossolimo St., Moscow, Russian Federation, 119021

Ghazaryan S.A.

Yerevan State Medical University after Mkhitar Heratsi, 2 Koryuna St., Erevan, Republic of Armenia, 0025

Continuous anti-glaucoma drug therapy as a risk factor of dry eye

Authors:

Erichev V.P., Petrov S.Iu., Volzhanin A.V., Ghazaryan S.A.

More about the authors

Journal: Russian Annals of Ophthalmology. 2019;135(6): 117‑123

DOI: 10.17116/oftalma2019135061117

Read: 9837 times

Download PDF (RU)
Contact the author
Table of contents

CONTINUOUS ANTI-GLAUCOMA DRUG THERAPY AS A RISK FACTOR OF DRY EYE
CONTINUOUS ANTI-GLAUCOMA DRUG THERAPY AS A RISK FACTOR OF DRY EYE

To cite this article:

Erichev VP, Petrov SIu, Volzhanin AV, Ghazaryan SA. Continuous anti-glaucoma drug therapy as a risk factor of dry eye. Russian Annals of Ophthalmology. 2019;135(6):117‑123. (In Russ.)
https://doi.org/10.17116/oftalma2019135061117

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Approaches for improvement of ocular surface condition in primary open-angle glaucoma. Russian Annals of Ophthalmology. 2024;(5):7-16
Perioperative prevention of bleeding in glaucoma surgery. Russian Annals of Ophthalmology. 2024;(5):118-124
The resu­lts of fistulizing glaucoma surgeries in pseudophackic patients. Russian Annals of Ophthalmology. 2025;(1):45-52
The possibilities of antioxidant neuroretinoprotection in the treatment of primary open-angle glaucoma. Russian Annals of Ophthalmology. 2025;(4):49-59
Electrophysiological methods in the diagnosis and moni­toring of glaucoma. Russian Annals of Ophthalmology. 2025;(4):102-109
Abstract:

A preservative is a mandatory component of the eye drops designed to prevent microbial contamination in an opened bottle. Most of the preservative agents are either detergents, or oxidants; the most widely used and well-studied preservative — benzalkonium chloride — is a detergent. Due to regular usage of glaucoma eye drops, cytotoxic impact of the preservatives on anterior eye surface is considered the principal cause of its pathology, which leads to a decrease in quality of life. The high cost of preservative-free pharmacological forms and the complicated process of developing new preservatives make the usage of eye drops with minimal required concentration of preservative agent and a moistening component a good compromise. The most commonly utilized moistening component is polyvinyl alcohol — synthetic polymeric hydrogel, which is also used in artificial tears and bioengineering.

Keywords:

glaucoma
preservatives
polyvinyl alcohol

Authors:

Erichev V.P.

FGBU "Nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ" RAMN, Moskva

Petrov S.Iu.

FGBU "NII glaznykh bolezneĭ" RAMN

Volzhanin A.V.

Research Institute of Eye Diseases, 11, A, B, Rossolimo St., Moscow, Russian Federation, 119021

Ghazaryan S.A.

Yerevan State Medical University after Mkhitar Heratsi, 2 Koryuna St., Erevan, Republic of Armenia, 0025

Close metadata

References:

  1. The United State Pharmacopoeia 24th revision. The National Formulary, 19th edition. Rockville, MD: The United States Pharmacopeial Convention, Inc.; 2000.
  2. European Pharmacopoeia, 7th edition Strasbourg: Council of Europe; 2010.
  3. Kallings LO, Ringertz O, Silverstolpe L. Microbiological contamination of medical preparations. Acta Pharm Suec. 1966;3(3):219-228.
  4. Baudouin C, Labbe A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29(4):312-334. https://doi.org/10.1016/j.preteyeres.2010.03.001
  5. Kim MS, Choi CY, Kim JM, Chang HR, Woo HY. Microbial contamination of multiply used preservative-free artificial tears packed in reclosable containers. Br J Ophthalmol. 2008;92(11):1518-1521. https://doi.org/10.1136/bjo.2008.144469
  6. Aslund B, Olson OT, Sandell E. Studies on in-use microbial contamination of eye drops. Acta Pharm Suec. 1978;15(5):389-394.
  7. Tasli H, Cosar G. Microbial contamination of eye drops. Cent Eur J Public Health. 2001;9(3):162-164.
  8. Templeton WC, 3rd, Eiferman RA, Snyder JW, Melo JC, Raff MJ. Serratia keratitis transmitted by contaminated eyedroppers. Am J Ophthalmol. 1982;93(6):723-726.
  9. Krishnan T, Sengupta S, Reddy PR, Ravindran RD. Secondary pseudomonas infection of fungal keratitis following use of contaminated natamycin eye drops: a case series. Eye (Lond). 2009;23(2):477-479. https://doi.org/10.1038/eye.2008.290
  10. Rahman MQ, Tejwani D, Wilson JA, Butcher I, Ramaesh K. Microbial contamination of preservative free eye drops in multiple application containers. Br J Ophthalmol. 2006;90(2):139-141. https://doi.org/10.1136/bjo.2005.078386
  11. Freeman PD, Kahook MY. Preservatives in topical ophthalmic medications: historical and clinical perspectives. Expert Review of Ophthalmology. 2009;4:59-64.
  12. Kahook MY, Travoprost Z. Ophthalmic solution: clinical safety and efficacy. Expert Review of Ophthalmology. 2007;2(3):363-368.
  13. Domagk G. Eine neue Klasse von Desinfectionsmitteln. Deutsche Medizin Wissenschafter. 1935(61):829-832.
  14. Charnock C. Are multidose over-the-counter artificial tears adequately preserved? Cornea. 2006;25(4):432-437. https://doi.org/10.1097/01.ico.0000183538.53017.69
  15. De Saint Jean M, Brignole F, Bringuier AF, Bauchet A, Feldmann G, Baudouin C. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci. 1999;40(3):619-630.
  16. Baudouin C, de Lunardo C. Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol. 1998;82(1):39-42.
  17. Stevens AM, Kestelyn PA, De Bacquer D, Kestelyn PG. Benzalkonium chloride induces anterior chamber inflammation in previously untreated patients with ocular hypertension as measured by flare meter: a randomized clinical trial. Acta Ophthalmol. 2012;90(3):221-224. https://doi.org/10.1111/j.1755-3768.2011.02338.x
  18. Miyake K, Ota I, Ibaraki N, Akura J, Ichihashi S, Shibuya Y, Maekubo K, Miyake S. Enhanced disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema by topical timolol and its preservative in early postoperative pseudophakia. Arch Ophthalmol. 2001;119(3):387-394.
  19. Burstein NL. Preservative cytotoxic threshold for benzalkonium chloride and chlorhexidine digluconate in cat and rabbit corneas. Invest Ophthalmol Vis Sci. 1980;19(3):308-313.
  20. Datta S, Baudouin C, Brignole-Baudouin F, Denoyer A, Cortopassi GA. The eye drop preservative benzalkonium chloride potently induces mitochondrial dysfunction and preferentially affects LHON mutant cells. Invest Ophthalmol Vis Sci. 2017;58(4):2406-2412. https://doi.org/10.1167/iovs.16-20903
  21. Gaidamaka TB, Senishin VI, Rafalyuk SYa. Influence of preservative benzalkonium chloride on lysosomal membranes of the anterior eye tissues. Oftalmologiya. Vostochnaya Evropa. 2015;2(25):49-55. (In Russ.)
  22. De Saint Jean M, Debbasch C, Brignole F, Rat P, Warnet JM, Baudouin C. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Curr Eye Res. 2000;20(2):85-94.
  23. Sherwood MB, Grierson I, Millar L, Hitchings RA. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon’s capsule in glaucomatous patients. Ophthalmology. 1989;96(3):327-335.
  24. Brandt JD, Wittpenn JR, Katz LJ, Steinmann WN, Spaeth GL. Conjunctival impression cytology in patients with glaucoma using long-term topical medication. Am J Ophthalmol. 1991;112(3):297-301.
  25. Baudouin C, Garcher C, Haouat N, Bron A, Gastaud P. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology. 1994;101(3):454-460.
  26. Costagliola C, Prete AD, Incorvaia C, Fusco R, Parmeggiani F, Di Giovanni A. Ocular surface changes induced by topical application of latanoprost and timolol: a short-term study in glaucomatous patients with and without allergic conjunctivitis. Graefes Arch Clin Exp Ophthalmol. 2001;239(11):809-814.
  27. Lebedev OI, Yavorsky AE, Kalizhnikova EA, Kovalevsky VV. Benzalkonium chloride as one of the causes of insufficient efficacy in glaucoma surgeries. Oftalmokhirurgiya. 2012;2:48-50. (In Russ.)
  28. Brignole-Baudouin F, Desbenoit N, Hamm G, Liang H, Both JP, Brunelle A, Fournier I, Guerineau V, Legouffe R, Stauber J, Touboul D, Wisztorski M, Salzet M, Laprevote O, Baudouin C. A new safety concern for glaucoma treatment demonstrated by mass spectrometry imaging of benzalkonium chloride distribution in the eye, an experimental study in rabbits. PLoS One. 2012;7(11):e50180. https://doi.org/10.1371/journal.pone.0050180
  29. Tereshchenko AV, Belyy YuA, Takhchidi EKh, Novikov SV, Maychuk NV, Usanova GYu. Experimental study of the effect of a 0,1% solution of benzalkonium chloride on the condition of the cornea in rabbits. Vestnik Orenburgskogo gosudarstvennogo universiteta. 2015;12(178):238-243. (In Russ.)
  30. Kahook MY. The Pros and Cons of Preservatives 2015. Available from: https://www.reviewofophthalmology.com/article/the-pros-and-cons-of-preservatives
  31. Becquet F, Goldschild M, Moldovan MS, Ettaiche M, Gastaud P, Baudouin C. Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface. Curr Eye Res. 1998;17(4):419-425.
  32. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2001;18(5):205-215.
  33. Tomlinson A, Trees GR. Effect of preservatives in artificial tear solutions on tear film evaporation. Ophthalmic Physiol Opt. 1991;11(1):48-52.
  34. Tripathi BJ, Tripathi RC. Cytotoxic effects of benzalkonium chloride and chlorobutanol on human corneal epithelial cells in vitro. Lens Eye Toxic Res. 1989;6(3):395-403.
  35. Rosenthal RA, Henry CL, Stone RP, Schlech BA. Anatomy of a regimen: consideration of multipurpose solutions during non-compliant use. Cont Lens Anterior Eye. 2003;26(1):17-26. https://doi.org/10.1016/S1367-0484(02)00085-1
  36. Labbé A, Pauly A, Liang H, Brignole-Baudouin F, Martin C, Warnet JM, Baudouin C. Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study. J Ocul Pharmacol Ther. 2006;22(4):267-278. https://doi.org/10.1089/jop.2006.22.267
  37. Lopez Bernal D, Ubels JL. Quantitative evaluation of the corneal epithelial barrier: effect of artificial tears and preservatives. Curr Eye Res. 1991;10(7):645-656.
  38. Choy CK, Cho P, Boost MV. Cytotoxicity and effects on metabolism of contact lens care solutions on human corneal epithelium cells. Clin Exp Optom. 2012;95(2):198-206. https://doi.org/10.1111/j.1444-0938.2011.00687.x
  39. Debbasch C, Brignole F, Pisella PJ, Warnet JM, Rat P, Baudouin C. Quaternary ammoniums and other preservatives’ contribution in oxidative stress and apoptosis on Chang conjunctival cells. Invest Ophthalmol Vis Sci. 2001;42(3):642-652.
  40. Yamazaki S, Nanno M, Kimura T, Suzumura H, Yoshikawa K. Effects of switching to SofZia-preserved travoprost in patients who presented with superficial punctate keratopathy while under treatment with latanoprost. Jpn J Ophthalmol. 2010;54(1):7-14. https://doi.org/10.1007/s10384-009-0754-8
  41. Tu EY. Balancing antimicrobial efficacy and toxicity of currently available topical ophthalmic preservatives. Saudi J Ophthalmol. 2014;28(3):182-187. https://doi.org/10.1016/j.sjopt.2014.06.006
  42. Nasser L, Rozycka M, Gomez Rendon G, Navas A. Real-life results of switching from preserved to preservative-free artificial tears containing hyaluronate in patients with dry eye disease. Clin Ophthalmol. 2018;12:1519-1525. https://doi.org/10.2147/OPTH.S160053
  43. Wang M, Li J, Li W, Du Z, Qin S. Preparation and characterization of novel poly (vinyl alcohol)/collagen double-network hydrogels. Int J Biol Macromol. 2018;118(Pt A):41-48. https://doi.org/10.1016/j.ijbiomac.2018.05.200
  44. Jiang S, Liu S, Feng W. PVA hydrogel properties for biomedical application. Journal of the Mechanical Behavior of Biomedical Materials. 2011;4(7):1228-1233. https://doi.org/10.1016/j.jmbbm.2011.04.005
  45. Mollazadeh S, Javadpour J, Khavandi A. Biomimetic synthesis and mechanical properties of hydroxyapatite/poly (vinyl alcohol) nanocomposites. Advances in Applied Ceramics. 2007;106:165-170.
  46. Anna T, Matteo D, Dagnija L. Calcium phosphate/polyvinyl alcohol composite hydrogels: A review on the freeze-thawing synthesis approach and applications in regenerative medicine. European Polymer Journal. 2017;95:547-565.
  47. Kuznetsova DS, Timashev PS, Bagratashvili VN, Zagaynova EV. Scaffold- and Cell System-Based Bone Grafts in Tissue Engineering (Review). Sovremennye tekhnologii v meditsine. 2014;6(4):201-212. (In Russ.)
  48. Garg T, Singh O, Arora S, Murthy R. Scaffold: a novel carrier for cell and drug delivery. Crit Rev Ther Drug Carrier Syst. 2012;29(1):1-63.
  49. Andersen FA. Final report on the safety assessment of polyvinyl alcohol. International Journal of Toxicology. 1998;17:67-92.
  50. Burnett CL. Polyvinyl alcohol. Int J Toxicol. 2017;36(5_suppl2):46-47. https://doi.org/10.1177/1091581817716650
  51. van de Berg NJ, Sanchez-Margallo JA, van Dijke AP, Lango T, van den Dobbelsteen JJ. A Methodical quantification of needle visibility and echogenicity in ultrasound images. Ultrasound Med Biol. 2019;45(4):998-1009. https://doi.org/10.1016/j.ultrasmedbio.2018.10.004
  52. Chanthasopeephan T, Desai JP, Lau AC. Modeling soft-tissue deformation prior to cutting for surgical simulation: finite element analysis and study of cutting parameters. IEEE Trans Biomed Eng. 2007;54(3):349-359. https://doi.org/10.1109/TBME.2006.886937
  53. Mano I, Goshima H, Nambu M, Iio M. New polyvinyl alcohol gel material for MRI phantoms. Magn Reson Med. 1986;3(6):921-926.
  54. Hubbell JA. Synthetic biodegradable polymers for tissue engineering and drug delivery. Current Opinion in Solid State and Materials Science. 1998;3(3):246-251.
  55. de Cesar Netto C, Godoy-Santos AL, Cabe TN, Roberts LE, Harnroongroj T, Deland J, Drakos M. The use of polyvinyl alcohol hydrogel implants in the lesser metatarsal heads. Is it safely doable? A cadaveric study. Foot Ankle Surg. 2019. https://doi.org/10.1016/j.fas.2018.12.009
  56. Weller WJ. Emerging technologies in upper extremity surgery: polyvinyl alcohol hydrogel implant for thumb carpometacarpal arthroplasty and processed nerve allograft and nerve conduit for digital nerve repairs. Orthop Clin North Am. 2019;50(1):87-93. https://doi.org/10.1016/j.ocl.2018.08.011
  57. Marin S, Albu Kaya MG, Ghica MV, Dinu-Pirvu C, Popa L, Udeanu DI, Mihai G, Enachescu M. Collagen-polyvinyl alcohol-indomethacin biohybrid matrices as wound dressings. Pharmaceutics. 2018;10(4). https://doi.org/10.3390/pharmaceutics10040224
  58. Safaee-Ardakani MR, Hatamian-Zarmi A, Sadat SM, Mokhtari-Hosseini ZB, Ebrahimi-Hosseinzadeh B, Rashidiani J, Kooshki H. Electrospun Schizophyllan/polyvinyl alcohol blend nanofibrous scaffold as potential wound healing. Int J Biol Macromol. 2019;127:27-38. https://doi.org/10.1016/j.ijbiomac.2018.12.256
  59. He X, Luzi F, Hao X, Yang W, Torre L, Xiao Z, Xie Y, Puglia D. Thermal, antioxidant and swelling behaviour of transparent polyvinyl (alcohol) films in presence of hydrophobic citric acid-modified lignin nanoparticles. Int J Biol Macromol. 2019;127:665-676. https://doi.org/10.1016/j.ijbiomac.2019.01.202
  60. Pruitt J, Giles T, Simmons K. In vitro contact angle and coefficient of friction profiles for daily disposable contact lenses. BCLA Conference; Birmingham, UK; 2010.
  61. Mahomed A, Ross G, Tighe B. Contact lenses and comfort enhancers: In vivo and in vitro release of soluble PVA. BCLA Conference; Brighton, UK; 2004.
  62. Peterson RC, Wolffsohn JS, Nick J, Winterton L, Lally J. Clinical performance of daily disposable soft contact lenses using sustained release technology. Cont Lens Anterior Eye. 2006;29(3):127-134. https://doi.org/10.1016/j.clae.2006.03.004
  63. Phan CM, Subbaraman LN, Jones LW. Uptake and release of polyvinyl alcohol from hydrogel daily disposable contact lenses. Optom Vis Sci. 2019;96(3):180-186. https://doi.org/10.1097/OPX.0000000000001351
  64. Phan CM, Walther H, Riederer D, Lau C, Lorenz KO, Subbaraman LN, Jones L. Analysis of polyvinyl alcohol release from commercially available daily disposable contact lenses using an in vitro eye model. J Biomed Mater Res B Appl Biomater. 2018. https://doi.org/10.1002/jbm.b.34259
  65. Matsuura K, Mori T, Miyamoto T, Suto C, Saeki Y, Tanaka S, Kawamura H, Ohkubo S, Tanito M, Inoue Y. Survey of Japanese ophthalmic surgeons regarding perioperative disinfection and antibiotic prophylaxis in cataract surgery. Clin Ophthalmol. 2014;8:2013-2018. https://doi.org/10.2147/OPTH.S64756
  66. Shibata Y, Tanaka Y, Tomita T, Taogoshi T, Kimura Y, Chikama T, Kihira K. Evaluation of corneal damage caused by iodine preparations using human corneal epithelial cells. Jpn J Ophthalmol. 2014;58(6):522-527. https://doi.org/10.1007/s10384-014-0348-y
  67. Brjesky VV, Radkhuan M. Glaucoma and the dry eye syndrome. Oftalmologicheskie vedomosti. 2014;7(3):37-49. (In Russ.)
  68. Shalelashvili S, Badur Kh, Oganesyan EA, Balabanyan VYu, Alyautdin RN. Design of topical ophthalmic formulations having enhanced bioavailability. Farmatsia. 2010;7:54-56. (In Russ.)
  69. Jain D, Carvalho E, Banthia AK, Banerjee R. Development of polyvinyl alcohol-gelatin membranes for antibiotic delivery in the eye. Drug Dev Ind Pharm. 2011;37(2):167-177. https://doi.org/10.3109/03639045.2010.502533
  70. Rossi GC, Tinelli C, Pasinetti GM, Milano G, Bianchi PE. Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol. 2009;19(4):572-579.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.